Edwards Lifesciences Corp (EW) reports robust 9% sales growth for 2024, driven by TMTT segment and strategic acquisitions, ...

Edwards maintained its 2025 financial guidance, targeting total company sales of $5.6 billion to $6 billion, with TAVR sales of $4.1 billion to $4.4 billion, TMTT sales of $500 million to $530 million ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

Edwards Lifesciences Corp (NYSE:EW) reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $0.59 against a ...

JAMESTOWN — Two Sanford Health Fargo cardiology providers offer outreach services at Sanford Jamestown 2nd Ave. Clinic. Outreach services are offered on the second and fourth Wednesday of every month.

Edwards Lifesciences stock surged late Tuesday — and could retake its 50-day and 200-day lines — after beating fourth-quarter ...

Edwards Lifesciences (NYSE: EW) shares got a boost after hours today on fourth-quarter results that came in ahead of the consensus forecast.

Reports Q4 revenue $1.39B, consensus $1.36B. Q4 TAVR sales grew 6%; constant currency sales grew 5%; Q4 TMTT sales grew 88% to $105 million ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

Silver Cross Hospital in New Lenox recently received a three-star rating from The Society of Thoracic Surgeons.

Despite guideline recommendations, the use of bioprosthetic heart valves has surpassed mechanical valves, but data from a large surgical database may lead to a reassessment of that practice.

Coronary events after TAVR are rare but impact survival. PCI improves outcomes, particularly in balloon-expandable valve ...